Search
Caspofungin
go.drugbank.com/drugs/DB00520ApprovedInvestigationalCaspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. … It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Products: CASPOFUNGINA 50 MG/VIAL POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE, CASPOVITAE® 50 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLEInsulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalFormerly called LYSPRO from the chemical nomenclature [LYS(B28), PRO(B29)], insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine … As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood.
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency. … A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesOteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … Oteseconazole is an azole metalloenzyme inhibitor that targets fungal CYP51.
Synonyms: VT-1161Piperacillin
go.drugbank.com/drugs/DB00319ApprovedInvestigationalIt is also used in combination with other antibiotics.
Mixtures: PIPTAZ-AFT POWDER FOR SOLUTION FOR INJECTION 4.5G/VIAL, KABICTAM® POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLETivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigational[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Everolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIt is currently used as an immunosuppressant to prevent rejection of organ transplants. … Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: Nat-everolimusAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. … [A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction
Ombitasvir
go.drugbank.com/drugs/DB09296ApprovedInvestigationalOmbutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Ombutasvir first came on the market as a fixed-dose combination product with [DB09183], [DB09297], and [DB00503] as the FDA-approved product Viekira Pak.
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.